Table 1.
Demographic and clinical characteristics of the study population, n = 300.
| Variables | |
|---|---|
| Patient Demographics | |
| Age (years) | 61 ± 11 |
| Body mass index (kg/m2) | 32.1 ± 8.4 |
| Men | 164 (55%) |
| Race | |
| White | 272 (90%) |
| Black | 23 (8%) |
| Other | 5 (2%) |
| Clinical Characteristics | |
| Flecainide | 153 (51%) |
| Propafenone | 147 (49%) |
| Concomitant AV nodal blockers | |
| Beta blockers | 133 (44%) |
| Calcium channel blockers | 49 (16%) |
| Both | 48 (16%) |
| CKD | 11 (4%) |
| COPD | 36 (12%) |
| Liver disease | 2 (1%) |
| Average EF (%) | 56.0 ± 5.4 |
| Prior ischemic evaluation | 195 (65%) |
Abbreviations: CKD = chronic kidney disease; COPD = chronic obstructive pulmonary disease EF = ejection fraction.